Primary Hyperparathyroidism is a condition characterized by the overproduction of parathyroid hormone (PTH) by one or more of the parathyroid glands. This hormonal excess leads to elevated levels of calcium in the blood (hypercalcemia), which can result in a variety of systemic complications, including osteoporosis, kidney stones, and cardiovascular issues. While surgery remains the definitive cure, the case documented by Dr. Ramadan suggests that the biological response to calcimimetic drugs like cinacalcet may be more complex than previously theorized.
Clinical Presentation and Initial Diagnosis
The case centered on a 68-year-old male patient who was referred to the endocrine clinic following routine laboratory screenings that indicated severe biochemical abnormalities. The patient’s serum calcium was recorded at 12.1 mg/dL, significantly exceeding the standard upper limit of approximately 10.5 mg/dL. Concurrently, his intact parathyroid hormone (PTH) levels were measured at 451 pg/mL, a figure nearly seven times the upper reference limit.
Further diagnostic testing painted a picture of advanced PHPT. Laboratory results showed a low serum phosphate level of 2.2 mg/dL, a common finding in PHPT due to the phosphaturic effects of PTH. A dual-energy X-ray absorptiometry (DEXA) scan revealed osteopenia, specifically a femoral neck T-score of −2.0, indicating significant bone density loss. To identify the source of the hormone excess, clinicians utilized high-resolution ultrasonography. The imaging identified a well-demarcated, hypoechoic mass measuring 2.3 × 1.7 × 3.0 cm located posterior to the inferior right thyroid lobe. The presence of peripheral vascular flow within the mass strongly suggested a parathyroid adenoma.
Under standard protocols, the patient was an immediate candidate for a parathyroidectomy, which boasts a success rate exceeding 95%. However, the clinical trajectory was diverted when a preoperative cardiac evaluation revealed severe multivessel coronary artery disease. The surgical team determined that the risks of anesthesia and surgery were too high until the patient’s cardiac status was stabilized. The patient underwent percutaneous coronary intervention (PCI) with stent placement, requiring a six-month regimen of dual antiplatelet therapy (DAPT).
The Pharmacological Intervention: A Bridge to Surgery
To manage the patient’s symptomatic hypercalcemia during the six-month waiting period for surgery, the medical team prescribed cinacalcet. Cinacalcet is an oral calcimimetic agent that increases the sensitivity of calcium-sensing receptors (CaSR) on the surface of the parathyroid gland. By mimicking the action of calcium, the drug signals the gland to reduce the secretion of PTH, thereby lowering serum calcium levels.
The patient began a dosage of 30 mg daily, which was eventually titrated to 30 mg twice daily. The primary goal was "bridge therapy"—stabilizing the patient’s biochemistry to prevent acute hypercalcemic crisis while he remained on antiplatelet medication.
Six months later, the patient returned for a follow-up, but his clinical presentation had shifted dramatically. He reported new-onset paresthesias, a tingling sensation often associated with low calcium levels. Laboratory tests confirmed a state of "frank hypocalcemia," with serum calcium dropping to 6.8 mg/dL and PTH plummeting to 14 pg/mL. In response, cinacalcet was discontinued, and the patient was started on oral calcium supplementation. Within one month of stopping the drug, his levels normalized to a calcium of 9.1 mg/dL and a PTH of 44 pg/mL.
The Vanishing Adenoma: A Deviation from Medical Norms
The most startling discovery occurred during a follow-up neck ultrasound. Clinicians expected to see the original 2.3 cm adenoma still present, as cinacalcet is not traditionally known to reduce tumor size; it merely manages the hormone output. Instead, the imaging revealed that the mass had regressed to 1.4 × 1.0 × 1.1 cm—a volume reduction of more than 50%.
"I remember staring at the ultrasound in clinic," Dr. Ramadan noted. "We couldn’t really believe the tumor had gotten smaller. Cinacalcet’s mechanism of action doesn’t cause shrinkage of a parathyroid adenoma."
Typically, when a patient stops taking cinacalcet, PTH and calcium levels rebound to their previous high levels because the underlying adenoma remains active. However, this patient remained in biochemical remission. At the one-year follow-up, his serum calcium was stable at 9.8 mg/dL. Nearly three years after the initial intervention, the patient’s calcium remained within normal limits at 8.9 mg/dL, maintained only by standard vitamin D supplementation.
Pathophysiological Theories: Apoplexy vs. Apoptosis
The research team explored several mechanisms to explain this "medical marvel." One prominent theory is "parathyroid apoplexy." This involves a spontaneous hemorrhagic infarction of the adenoma, where the blood supply is cut off, leading to rapid tissue death (necrosis) and a sudden drop in hormone production. While apoplexy can cause remission, it is usually accompanied by acute symptoms such as sudden neck pain, swelling, or difficulty swallowing. Dr. Ramadan’s patient, however, experienced a gradual regression without acute physical trauma or pain.
A second, more provocative theory involves the upregulation of the calcium-sensing receptor (CaSR). It is hypothesized that cinacalcet may, in rare instances, restore normal signaling pathways in adenomatous tissue, triggering programmed cell death (apoptosis). In vitro studies have suggested that calcimimetics can have a dose-dependent apoptotic effect on parathyroid cells. Dr. Ramadan suggested that the clinical evidence in this case pointed more toward slow apoptotic involution than an acute vascular event, though definitive proof would require a histological biopsy.
The team also considered the possibility of parathyroid carcinoma, given the patient’s extremely high initial PTH levels. Carcinoma typically presents with PTH levels more than three times the normal limit. However, the ultrasound characteristics—homogeneous and well-demarcated—and the sustained long-term remission without recurrence argued strongly against malignancy.
Broader Implications for PHPT Treatment
Dr. Ramadan’s findings add to a very small body of literature—only a handful of cases globally—documenting cinacalcet-associated remission. These rare cases include instances of total adenoma disappearance and long-term remission lasting nearly a decade.
The implications of this research are particularly relevant for patients who are "non-surgical candidates." While surgery remains the gold standard, this case opens a dialogue about whether certain subsets of patients might benefit from aggressive medical management as a primary treatment rather than just a bridge. However, Dr. Ramadan cautions that a prospective clinical trial would be difficult to conduct. Because the cure rate for surgery is so high, it is ethically challenging to deny patients surgery in favor of a medical trial for a phenomenon that remains "sporadic and rare."
The next logical step in this research involves histopathology. Examining the cellular architecture of adenomas in patients who respond this way to cinacalcet could unlock new understanding of the CaSR pathway and potentially lead to new targeted therapies.
Professional Development and the Role of the Endocrine Society
Beyond the clinical findings, Dr. Ramadan’s journey highlights the importance of professional mentorship and institutional support in medical research. Her transition from a general interest in endocrinology to a focused niche in bone and calcium metabolism was facilitated by her Early Career Membership in the Endocrine Society.
This program, designed for endocrinologists in their first three years post-training, provides a framework for professional development that Dr. Ramadan credits with helping her "find her voice" in the field. Through the society’s annual conference, ENDO, she was able to observe experienced clinicians navigate complex cases in real-time and access diagnostic technologies that she subsequently integrated into her clinical practice at Boston Medical Center.
Working within a safety-net hospital like Boston Medical Center has also allowed Dr. Ramadan to observe the intersection of endocrine disorders and health disparities. Research indicates that African American women face a higher risk of PHPT and often present with more severe biochemical symptoms. Dr. Ramadan’s future research aims to investigate why recurrence happens in certain populations and how to optimize management for underserved communities who may face barriers to surgical care.
Conclusion and Future Outlook
As Dr. Ramadan prepares to relocate to Seattle for her fellowship, her work stands as a reminder of the value of the "case report" in modern medicine. While large-scale trials provide the backbone of evidence-based practice, individual cases like the "vanishing adenoma" provide the anomalies that drive new hypotheses and deeper investigations into cellular biology.
For the medical community, the case of the 68-year-old man who avoided surgery through an unanticipated pharmacological response serves as a prompt to remain observant. While cinacalcet is currently viewed as a management tool, the possibility that it could—under specific biological conditions—induce remission offers a glimpse into a future where medical management of primary hyperparathyroidism might one day rival surgical intervention for a specific subset of the population. For now, Dr. Ramadan’s research ensures that this rare clinical occurrence is documented, analyzed, and available to inform the next generation of endocrine specialists.
